Sesame Partners With Novo Nordisk to Launch Oral Wegovy Pill for Weight Management

Sesame, a leading direct-pay digital healthcare platform, has announced a new partnership with Novo Nordisk to support the nationwide launch of the oral version of Wegovy, a GLP-1 medication used in weight management.

The collaboration marks a significant step forward in improving access to obesity treatment. Through Sesame’s online platform, patients can now book virtual consultations with licensed clinicians to assess suitability for the new oral GLP-1 therapy. Where clinically appropriate, prescriptions can be issued directly following evaluation.

A New Chapter in GLP-1 Weight-Loss Treatment

Wegovy has already become one of the most recognized GLP-1 treatments for obesity management. Traditionally administered via injection, the introduction of an oral formulation offers patients a more convenient option.

For many individuals, the idea of taking a daily pill instead of weekly injections may improve adherence and comfort. As demand for GLP-1 medications continues to rise across the UK and globally, oral alternatives are expected to broaden patient access and acceptance.

Direct-to-Patient Access Through Digital Care

As a NovoCare Recognized Care Provider, Sesame provides a streamlined, digital-first pathway to treatment. Patients can select clinicians from a nationwide network and book same-day virtual appointments through the platform’s website or mobile app.

Importantly, Sesame operates on a cash-pay model. This removes insurance intermediaries and allows patients to view transparent pricing upfront. For pharmacy audiences, this reflects a wider shift toward accessible, consumer-focused healthcare delivery.

Transparent Pricing and Subscription Support

Sesame’s weight management program begins at $99 per month. The service includes:

• Ongoing video consultations
• Secure clinician messaging
• Laboratory monitoring
• Personalised advice on diet, exercise, and sleep

Medication pricing varies based on coverage. GLP-1 treatments start at $25 per month for eligible commercially insured patients, while self-pay pricing begins at $149 per month.

Clear pricing structures remain a key factor for patients exploring weight-loss injections or oral GLP-1 options, particularly in markets where insurance coverage varies.

Why This Matters for UK Pharmacy Patients

Although Sesame currently operates in the United States, the partnership highlights an important global trend. Demand for GLP-1 therapies continues to surge in the UK, with increasing patient interest in alternatives to injectable treatments.

Pharmacies across the UK are seeing growing enquiries about Wegovy, semaglutide, and other GLP-1 medications. The development of an oral formulation could reshape prescribing patterns and improve patient uptake, especially among those hesitant about injections.

Furthermore, digital consultations and remote prescribing are becoming more common in UK pharmacy practice. Online assessment pathways, supported by clinician oversight and monitoring, are increasingly part of modern weight management services.

Industry Leaders Highlight Simpler Access

Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk, described the oral Wegovy pill as offering patients a convenient new option in obesity medicine. Sesame CEO and Co-Founder David Goldhill emphasised that the collaboration creates a simple and direct route to care, supported by transparent pricing.

Their statements reflect a broader move toward integrated pharmaceutical and digital health partnerships designed to reduce friction in patient access.

The Future of Obesity Treatment

The launch of oral Wegovy signals continued innovation within GLP-1 therapy. As pharmaceutical companies invest in alternative delivery methods, the focus remains on improving patient adherence, safety, and accessibility.

For pharmacy providers and weight management services, this evolution reinforces the importance of the following:

• Clear patient education
• Safe prescribing frameworks
• Ongoing clinical monitoring
• Transparent pricing structures

As obesity remains a significant public health concern in the UK, new treatment formats and digital access models are likely to play a growing role in how patients receive care.